Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.

The Journal of investigative dermatology - 1 Feb 2000

Ma Y, Carter E, Wang X, Shu C, McMahon G, Longley B J

Abstract excerpt

Mastocytosis is a neoplastic disease caused at least in part by somatic mutations of the c-KIT proto-oncogene resulting in constitutive activation of its protein product, KIT, the receptor tyrosine kinase for stem cell factor. KIT stimulates mast cell proliferation and prevents apoptosis of neoplastic mast cells. To develop potential therapies for mastocytosis we used indolinones, small molecules that inhibit...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proto-Oncogene Proteins c-kit
Share to Gene Expression Regulation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to KIT gene

Share to Indoles

Share to Mast Cells

Share to Mutation

Share to Proto-Oncogene Mas

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 10652004
DOI: 10.1046/j.1523-1747.2000.00888.x

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Indolinone derivatives inhibit constitutively activated KIT mutants and kill neoplastic mast cells.PMID 10652004Read ↗

Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.Semantic proximity Read ↗

Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic MastocytosisSemantic proximity Read ↗

Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.Semantic proximity Read ↗

Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis.Semantic proximity Read ↗

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.Semantic proximity Read ↗

Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disordersSemantic proximity Read ↗

KIT mutations in mastocytosis and their potential as therapeutic targets.Semantic proximity Read ↗

On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Semantic proximity Read ↗

Targeting c-Kit mutations: basic science to novel therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.